P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 990-991
10.1097/01.hs9.0000847268.67095.fc